Zytiga (Abiraterone Acetate) Copay Assistance Program

Zytiga (abiraterone acetate) copay assistance refers to financial support programs — including manufacturer copay cards, patient assistance programs, and nonprofit foundation grants — that help reduce the out-of-pocket cost of Zytiga or generic abiraterone for eligible patients. QuickRx Specialty Pharmacy provides free enrollment support to connect prostate cancer patients with every available savings option based on their insurance coverage and financial situation. Our patient navigators handle all application paperwork at no charge.

Yes — copay card programs are available for Zytiga (abiraterone acetate) for eligible patients with commercial insurance. These programs can significantly reduce monthly out-of-pocket costs for abiraterone treatment. Medicare and Medicaid patients cannot use manufacturer copay cards due to federal regulations, but other options may be available.

QuickRx patient navigators verify your eligibility, manage the copay card enrollment process on your behalf, and apply the savings directly through our pharmacy — all at no cost to you. Call (917) 830-2525 to get started.

Eligibility for Zytiga copay assistance varies by program type. Manufacturer copay card programs are generally available to patients with commercial (private) insurance. Patient assistance programs are typically available to patients who are uninsured, underinsured, or covered by government insurance such as Medicare or Medicaid.

Common Eligibility Factors:

• Commercial insurance: Copay card programs — may significantly reduce monthly costs
• Medicare: Cannot use copay cards, but foundation grants and PAPs may be available
• Uninsured or underinsured: Patient assistance programs may provide abiraterone at low or no cost based on income
• Generic abiraterone: Additional savings options may exist beyond brand Zytiga programs

QuickRx evaluates your specific situation and identifies the programs you are most likely to qualify for at no cost. Call (917) 830-2525 to speak with a patient navigator.

No. QuickRx Specialty Pharmacy provides Zytiga copay assistance enrollment support as a completely free service. There are no fees, no hidden charges, and no obligation. Our patient navigator team assists with abiraterone applications because we believe cost should never be a barrier to prostate cancer treatment.

What QuickRx Does For Free:

• Reviews your insurance coverage and identifies all available programs
• Evaluates both brand Zytiga and generic abiraterone savings options
• Completes copay card and patient assistance applications on your behalf
• Coordinates with your oncologist for required documentation
• Manages ongoing renewals and insurance changes
• Provides continuous support throughout your abiraterone treatment

Medicare patients cannot use manufacturer copay cards due to federal regulations. However, other financial assistance options may still be available for Zytiga or generic abiraterone.

Options for Medicare Patients:

• Patient assistance programs: May provide abiraterone at reduced or no cost based on financial need
• Independent foundation grants: Disease-specific nonprofits focused on prostate cancer may offer assistance regardless of insurance type
• Generic abiraterone: May be covered at a lower cost tier under your Medicare Part D plan
• Medicare Extra Help / Low-Income Subsidy: May reduce specialty drug costs for qualifying patients
• State pharmaceutical assistance programs: Availability varies by state

QuickRx patient navigators can review your specific Medicare coverage and identify all available options at no cost to you. Call (917) 830-2525.

Without insurance or copay assistance, Zytiga (abiraterone acetate) can be very expensive. Generic abiraterone is available and typically costs significantly less than brand Zytiga, making it an important option for patients facing high out-of-pocket costs.

Factors That Affect Abiraterone Cost:

• Brand vs. generic: Generic abiraterone acetate is available and typically costs much less than brand Zytiga or Yonsa
• Dose prescribed: Zytiga is available in 250 mg and 500 mg tablets; Yonsa in 125 mg tablets
• Insurance coverage: Many plans cover abiraterone with varying copay amounts
• Pharmacy pricing: Prices vary significantly between pharmacies

Contact QuickRx at (917) 830-2525 to explore all copay assistance options that may help reduce your Zytiga costs — including both brand and generic abiraterone programs.

Zytiga, Yonsa, and generic abiraterone all contain the same active ingredient (abiraterone acetate) but have different formulations and dosing requirements.

Key Differences:

• Zytiga: Brand name conventional formulation; available in 250 mg and 500 mg tablets; must be taken on an empty stomach (1 hour before or 2 hours after food)
• Yonsa: Brand name micronized (fine particle) formulation; available in 125 mg tablets; can be taken with or without food; different dosing than Zytiga
• Generic abiraterone: Same as Zytiga formulation; available from multiple manufacturers; typically costs significantly less than brand versions

Important: The formulations are NOT interchangeable. Do not substitute between Zytiga, Yonsa, and generic abiraterone without consulting your healthcare provider.

Zytiga (abiraterone acetate) is an antiandrogen medication used to treat metastatic prostate cancer. It works by blocking CYP17, an enzyme required for androgen (male hormone) production in the body.

FDA-Approved Indications:

• Metastatic castration-resistant prostate cancer (mCRPC): In combination with prednisone (Zytiga) or methylprednisolone (Yonsa)
• Metastatic high-risk castration-sensitive prostate cancer (mCSPC): In combination with prednisone (Zytiga)

Abiraterone is always taken in combination with a corticosteroid (prednisone or methylprednisolone) and is used alongside other prostate cancer treatments. Patients should also receive a GnRH analog concurrently or have had a bilateral orchiectomy.

The standard dose of abiraterone depends on which formulation is prescribed.

Dosing by Formulation:

• Zytiga (conventional tablets): 1,000 mg once daily in combination with prednisone 5 mg twice daily (mCRPC) or once daily (mCSPC)
• Yonsa (micronized formulation): 500 mg once daily in combination with methylprednisolone 4 mg twice daily

Important Administration Notes:

• Zytiga: Must be taken on an empty stomach — at least 1 hour before and 2 hours after food; taking with food can increase drug levels up to 10-fold
• Yonsa: May be taken with or without food
• Swallow tablets whole with water — do not crush or chew

Your doctor determines the appropriate dose based on your condition. Dose adjustments may be needed for liver impairment. Always follow your healthcare provider’s specific instructions.

Abiraterone is always prescribed with a corticosteroid to reduce the risk of certain side effects caused by the drug’s mechanism of action. By blocking CYP17, abiraterone can lead to increased mineralocorticoids, which cause hypertension, low potassium, and fluid retention. The corticosteroid helps prevent or reduce these effects.

Typical Corticosteroid Dosing:

• With Zytiga for mCRPC: Prednisone 5 mg twice daily
• With Zytiga for mCSPC: Prednisone 5 mg once daily
• With Yonsa: Methylprednisolone 4 mg twice daily

Do not stop taking your corticosteroid without talking to your doctor, as this could lead to adrenal insufficiency.

Like all medications, abiraterone can cause side effects. Most common side effects include fatigue, joint pain, swelling, and hot flashes.

Most Common Side Effects (occurring in more than 10% of patients):

• General: Fatigue (39%), insomnia (14%)
• Cardiovascular: Edema/swelling (25–27%), hypertension (9–37%)
• Gastrointestinal: Constipation (23%), diarrhea (18–22%)
• Endocrine/metabolic: Hot flashes (15–22%), low potassium
• Musculoskeletal: Joint pain, joint swelling, muscle pain
• Respiratory: Cough (7–17%), shortness of breath (12%)

Tell your doctor about any side effects you experience. Some may require monitoring or dose adjustment.

Contact your doctor immediately if you experience any of the following serious side effects.

Serious Side Effects Requiring Medical Attention:

• Liver problems: Dark urine, fatigue, loss of appetite, stomach pain, light-colored stools, vomiting, yellowing of skin or eyes
• Heart problems: Abnormal heartbeat, swelling, weight gain, trouble breathing
• High blood pressure: Severe headache, dizziness, passing out, vision changes
• Low potassium: Mood changes, confusion, muscle pain or weakness, abnormal heartbeat, seizures
• Adrenal insufficiency: Severe nausea or vomiting, dizziness, muscle weakness, extreme fatigue, mood changes, weight loss
• Severe allergic reactions: Rash, hives, swelling of face, lips, tongue, or throat, trouble breathing

Severe hepatotoxicity (liver damage), including acute liver failure and death, has been reported rarely. This information is for educational purposes only — always review all risks with your prescribing oncologist.

Yes. Abiraterone has several clinically important drug interactions. Always inform your oncologist and pharmacist of all medications, supplements, and herbal products you are taking.

Notable Abiraterone Drug Interactions:

• Strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine): May significantly decrease abiraterone levels — avoid or adjust dose
• CYP2D6 substrates (metoprolol, dextromethorphan): Abiraterone may increase levels of these medications — monitor closely
• Radium Ra 223: Combination with abiraterone plus corticosteroid is NOT recommended due to increased risk of fractures and death
• Spironolactone: May decrease the therapeutic effects of abiraterone — consider alternatives
• Thiazolidinediones or repaglinide: May increase risk of severe low blood sugar

QuickRx pharmacists perform thorough drug interaction reviews as part of the dispensing process. Call (917) 830-2525 with any questions.

Regular monitoring is essential during abiraterone treatment to detect and manage potential side effects early.

Required Monitoring:

• Liver function tests (ALT, AST, bilirubin): Before treatment, every 2 weeks for the first 3 months, then monthly
• Potassium levels: Before treatment and at least monthly
• Blood pressure: Before treatment and at least monthly
• Blood sugar: In patients with diabetes, during and after stopping treatment
• Fluid retention: Monitor for swelling and unexplained weight gain

Patients with moderate liver impairment may require more frequent monitoring. Always attend all scheduled lab appointments as directed by your oncologist.

Certain patients should not take abiraterone or should use it with caution.

Use Caution or Avoid If You Have:

• Severe liver impairment: Abiraterone is not recommended for patients with Child-Turcotte-Pugh class C liver disease
• Cardiovascular disease: Monitor closely if you have heart failure, recent heart attack, or arrhythmias
• Diabetes: Severe hypoglycemia has been reported, especially with certain diabetes medications

Pregnancy Considerations:

• Abiraterone is not indicated for use in females
• Patients with partners who could become pregnant should use effective contraception during treatment and for 3 weeks after the last dose
• Pregnant individuals should wear gloves if handling abiraterone tablets

Always discuss your full medical history with your oncologist before starting abiraterone.

Treatment duration depends on your individual response to therapy and tolerance of side effects. Abiraterone is typically continued until disease progression or unacceptable toxicity occurs.

Your oncologist will monitor your response through PSA levels, imaging, and symptom assessment throughout treatment. Do not stop or change your dose without consulting your healthcare provider.

If you have questions about your Zytiga treatment duration or need help affording ongoing abiraterone therapy, contact QuickRx at (917) 830-2525. Our patient navigators provide continuous support throughout your treatment — including managing copay assistance renewals each year.

Yes. QuickRx Specialty Pharmacy is licensed to dispense and ship Zytiga (abiraterone acetate) and generic abiraterone to patients in all 50 states. We provide free home delivery and ensure medications are properly packaged and shipped to maintain integrity.

Why Patients Choose QuickRx for Zytiga:

• Nationwide shipping to all 50 states
• Free copay assistance enrollment for both brand Zytiga and generic abiraterone
• Dedicated patient navigators specializing in prostate cancer and oncology
• Prior authorization support and appeal assistance
• URAC- and ACHC-accredited specialty pharmacy
• Personal, one-on-one support from enrollment through ongoing treatment

Call us at (917) 830-2525 or complete the form on this page to get started today.